Inflammatory and Neurodegenerative Pathways in Depression: A New Avenue for Antidepressant Development?

E-ISSN： 1875-533x|18|2|245-255

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.18, Iss.2, 2011-01, pp. : 245-255

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI?

By Dawson Lee A

Expert Opinion on Drug Discovery, Vol. 8, Iss. 12, 2013-12 ,pp. : 1529-1539

Informa Healthcare

Access to resources Recommend Favorite

New Approaches to Antidepressant Drug Design: Cytokine-Regulated Pathways

Current Pharmaceutical Design, Vol. 15, Iss. 14, 2009-05 ,pp. : 1683-1687

Bentham Science Publishers

Access to resources Recommend Favorite

Antidepressant therapy: new targets for drug development

Expert Opinion on Therapeutic Patents, Vol. 11, Iss. 11, 2001-11 ,pp. : 1693-1711

Informa Healthcare

Access to resources Recommend Favorite

Neurogenesis as a New Target for the Development of Antidepressant Drugs

Current Pharmaceutical Design, Vol. 20, Iss. 23, 2014-05 ,pp. : 3763-3775

Bentham Science Publishers

Access to resources Recommend Favorite

Gene regulation as a potential avenue for the treatment of neurodegenerative disorders

By Brown David R

Expert Opinion on Drug Discovery, Vol. 4, Iss. 5, 2009-05 ,pp. : 515-524

Informa Healthcare

Access to resources Recommend Favorite